Jul212015

Specific subtype of diffuse large B-cell lymphoma more likely to respond to ibrutinib

Study shows promise of precision medicine for most common type of lymphoma

A recent study shows that patients with a specific molecular subtype of diffuse large B-cell lymphoma (DLBCL) are more likely to respond to ibrutinib (Imbruvica) than patients with another molecular subtype of the disease.

Diffuse large B-cell lymphoma (DLBCL) - an aggressive (fast-growing) lymphoma - is the most common type of non-Hodgkin’s lymphoma (NHL).

The phase II trial, conducted by the National Cancer Institute (NCI) and Pharmacyclics, showed that patients with the activated B-cell-like (ABC) subtype of DLBCL were more likely to respond to ibrutinib than patients with the germinal center B-cell-like (GCB) subtype of DLBCL.

NIH/National Cancer Institute. "Study shows promise of precision medicine for most common type of lymphoma." ScienceDaily. ScienceDaily, 20 July 2015.

Targeting B-Cell Receptor Signaling with Ibrutinib in Diffuse Large B-Cell Lymphoma. Nature Medicine, July 2015

 

Like with Social Media